HALEOS LABS LIMITED
HALEOS LABS LIMITED (HALEOSLABS) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
haleoslabs.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69 Cr | 72 Cr | 90 Cr | 93 Cr | 78 Cr | 85 Cr | 89 Cr | 83 Cr | 81 Cr | 95 Cr | 75 Cr | 73 Cr |
| Operating expenses (approx.) | 61 Cr | 63 Cr | 79 Cr | 76 Cr | 70 Cr | 72 Cr | 82 Cr | 71 Cr | 68 Cr | 81 Cr | 71 Cr | 64 Cr |
| EBITDA | 8 Cr | 9 Cr | 11 Cr | 16 Cr | 9 Cr | 13 Cr | 7 Cr | 12 Cr | 14 Cr | 14 Cr | 4 Cr | 9 Cr |
| OPM % | 11.4% | 12.9% | 12.6% | 17.6% | 10.9% | 15.1% | 8.3% | 14.2% | 16.7% | 14.8% | 5.5% | 12.5% |
| Other income | 0.34 Cr | 0.58 Cr | 2 Cr | 0.44 Cr | 2 Cr | 0.06 Cr | 2 Cr | 1.00 Cr | 0.42 Cr | 0.18 Cr | 2 Cr | 0.46 Cr |
| Interest | 3 Cr | 2 Cr | 3 Cr | 2 Cr | 2 Cr | 2 Cr | 2 Cr | 2 Cr | 2 Cr | 2 Cr | 1 Cr | 2 Cr |
| Depreciation | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr |
| Profit before tax | 2 Cr | 4 Cr | 7 Cr | 11 Cr | 5 Cr | 7 Cr | 4 Cr | 7 Cr | 8 Cr | 9 Cr | 0.91 Cr | 3 Cr |
| Tax % | 126.7% | -8.2% | 8.8% | 33.3% | 29.8% | 29.8% | 11.3% | 37.6% | 24.3% | 24.3% | 62.0% | 46.5% |
| Net profit | -0.44 Cr | 4 Cr | 6 Cr | 7 Cr | 3 Cr | 5 Cr | 3 Cr | 4 Cr | 6 Cr | 7 Cr | 0.34 Cr | 2 Cr |
| EPS (₹) | ₹2.20 | ₹14.24 | ₹19.53 | ₹23.15 | ₹15.46 | ₹18.08 | ₹9.83 | ₹13.75 | ₹20.19 | ₹21.89 | ₹1.44 | ₹8.75 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 261 Cr | 266 Cr | 350 Cr | 316 Cr | 306 Cr | 345 Cr | 334 Cr | Sign in for TTM |
| Operating expenses (approx.) | 235 Cr | 235 Cr | 316 Cr | 287 Cr | 275 Cr | 300 Cr | 289 Cr | Sign in for TTM |
| EBITDA | 25 Cr | 30 Cr | 34 Cr | 29 Cr | 31 Cr | 45 Cr | 45 Cr | Sign in for TTM |
| OPM % | 9.7% | 11.4% | 9.8% | 9.1% | 10.2% | 13.1% | 13.4% | Sign in for TTM |
| Other income | 2 Cr | 2 Cr | 2 Cr | 3 Cr | 4 Cr | 5 Cr | 2 Cr | Sign in for TTM |
| Interest | 5 Cr | 5 Cr | 6 Cr | 7 Cr | 10 Cr | 9 Cr | 6 Cr | Sign in for TTM |
| Depreciation | 8 Cr | 8 Cr | 10 Cr | 11 Cr | 15 Cr | 15 Cr | 15 Cr | Sign in for TTM |
| Profit before tax | 15 Cr | 20 Cr | 33 Cr | 17 Cr | 10 Cr | 26 Cr | 25 Cr | Sign in for TTM |
| Tax % | 30.6% | 30.7% | 22.7% | 31.4% | 35.7% | 28.5% | 29.4% | Sign in for TTM |
| Net profit | 10 Cr | 14 Cr | 25 Cr | 11 Cr | 6 Cr | 19 Cr | 18 Cr | Sign in for TTM |
| EPS (₹) | ₹33.68 | ₹44.84 | ₹83.68 | ₹37.92 | ₹30.08 | ₹66.51 | ₹57.26 | Sign in for TTM |
| Dividend payout % | — | — | 1.8% | 4.0% | 7.2% | 2.4% | 2.5% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr |
| Reserves | 113 Cr | 126 Cr | 149 Cr | 166 Cr | 174 Cr | 194 Cr | 211 Cr |
| Borrowings | — | — | — | 99 Cr | 98 Cr | 84 Cr | 109 Cr |
| Other liabilities | — | — | — | 108 Cr | 99 Cr | 94 Cr | 116 Cr |
| Total liabilities | — | — | — | 395 Cr | 391 Cr | 390 Cr | 454 Cr |
| Fixed assets (net) | — | — | — | 227 Cr | 221 Cr | 230 Cr | 267 Cr |
| CWIP | — | — | — | 0.85 Cr | 6 Cr | 0.40 Cr | 10 Cr |
| Investments | — | — | — | 0.04 Cr | 0.04 Cr | 0.04 Cr | 0.04 Cr |
| Inventories | — | — | — | 86 Cr | 81 Cr | 67 Cr | 80 Cr |
| Trade receivables | — | — | — | 46 Cr | 51 Cr | 69 Cr | 61 Cr |
| Cash & bank | — | — | — | 1 Cr | 0.57 Cr | 0.50 Cr | 1 Cr |
| Other assets | — | — | — | 34 Cr | 30 Cr | 23 Cr | 35 Cr |
| Total assets | — | — | — | 395 Cr | 391 Cr | 390 Cr | 454 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | -11 Cr | 15 Cr | 24 Cr | 34 Cr | 37 Cr |
| Cash from investing | — | — | -7 Cr | -31 Cr | -18 Cr | -15 Cr | -58 Cr |
| Cash from financing | — | — | 11 Cr | 17 Cr | -7 Cr | -19 Cr | 21 Cr |
| Net cash flow | — | — | -8 Cr | 0.29 Cr | -0.71 Cr | -0.07 Cr | 0.71 Cr |
| Free cash flow (OCF − Capex) | — | — | -62 Cr | -34 Cr | 3 Cr | 19 Cr | -21 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | 17.1% | 18.6% | 25.5% | 8.2% | 6.9% | 11.8% | 9.4% |
| ROE % | 8.8% | 10.5% | 16.6% | 6.1% | 4.7% | 9.5% | 7.5% |
| Debtor days | — | — | — | 53 | 61 | 73 | 67 |
| Inventory days | — | — | — | 183 | 197 | 164 | 198 |
| Days payable | — | — | — | 127 | 144 | 129 | 152 |
| Cash conversion cycle | — | — | — | 110 | 115 | 107 | 113 |
| Debt / equity | — | — | — | 0.59 | 0.55 | 0.43 | 0.51 |
| Current ratio | — | — | — | 1.19 | 1.07 | 1.06 | 1.04 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 3.39 | 3.12 | 1.85 | 2.41 |
Compare with peers
Loading peers…